Milestone Cuts 30% of Costs, Extends Cash Runway to Late 2028 as CFO and CMO Exit
MIST is trading near its 52-week low of $0.631 (14% above the low).
Summary
Milestone reported Q3 2026 CARDAMYST net product revenue of $1.0 million, up 73% from the second quarter, with roughly 3,400 prescriptions from about 1,600 unique prescribers since launch and payer coverage at about two-thirds of commercially covered lives. The company is cutting operating expenses by approximately 30%, including bringing its ~45-person sales force in-house and reducing headquarters staff, with about $2 million in one-time charges and completion targeted for Q1 2027. CFO Amit Hasija and CMO David Bharucha have both left the leadership team; Anthony Krick, VP of Finance, is now Principal Financial and Principal Accounting Officer. An amendment with RTW extends the payment-in-kind interest period on the convertible notes from March 31, 2027 to March 2029. Cash of $145.4 million as of September 30 is now expected to fund operations into late 2028, more than a year beyond prior guidance and past the AFib-RVR Phase 3 (ReVeRA-301) topline readout expected in the second half of 2028. The quarter still carried a $25.8 million net loss and SG&A of $24.2 million against $1.0 million of product revenue, so the cuts are a runway fix rather than a profitability story.
At the time of this announcement, MIST was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.6M. The 52-week trading range was $0.63 to $3.06. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.